These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 8042819)
1. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Consideration of noninvasive management. Stein PD; Hull RD; Raskob G Ann Intern Med; 1994 Sep; 121(5):313-7. PubMed ID: 8042819 [TBL] [Abstract][Full Text] [Related]
2. Safety of thrombolytic therapy in elderly patients with massive pulmonary embolism: a comparison with nonelderly patients. Meneveau N; Bassand JP; Schiele F; Bouras Y; Anguenot T; Bernard Y; Schultz R J Am Coll Cardiol; 1993 Oct; 22(4):1075-9. PubMed ID: 8409043 [TBL] [Abstract][Full Text] [Related]
3. Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism. Meyer G; Gisselbrecht M; Diehl JL; Journois D; Sors H Am J Med; 1998 Dec; 105(6):472-7. PubMed ID: 9870831 [TBL] [Abstract][Full Text] [Related]
4. Relative risks of anticoagulant treatment of acute pulmonary embolism based on an angiographic diagnosis vs a ventilation/perfusion scan diagnosis. Stein PD; Hull RD Chest; 1994 Sep; 106(3):727-30. PubMed ID: 8082349 [TBL] [Abstract][Full Text] [Related]
6. Thrombolytic Therapy by Tissue Plasminogen Activator for Pulmonary Embolism. Islam MS Adv Exp Med Biol; 2017; 906():67-74. PubMed ID: 27628004 [TBL] [Abstract][Full Text] [Related]
7. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. Chatterjee S; Chakraborty A; Weinberg I; Kadakia M; Wilensky RL; Sardar P; Kumbhani DJ; Mukherjee D; Jaff MR; Giri J JAMA; 2014 Jun; 311(23):2414-21. PubMed ID: 24938564 [TBL] [Abstract][Full Text] [Related]
8. Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Mikkola KM; Patel SR; Parker JA; Grodstein F; Goldhaber SZ Am Heart J; 1997 Jul; 134(1):69-72. PubMed ID: 9266785 [TBL] [Abstract][Full Text] [Related]
9. Thrombolysis for acute intermediate-risk pulmonary embolism: A meta-analysis. Gao GY; Yang P; Liu M; Ding M; Liu GH; Tong YL; Yang CY; Meng FB Thromb Res; 2015 Nov; 136(5):932-7. PubMed ID: 26384442 [TBL] [Abstract][Full Text] [Related]
10. Risk factors associated with bleeding after alteplase administration for pulmonary embolism: a case-control study. Curtis GM; Lam SW; Reddy AJ; Bauer SR Pharmacotherapy; 2014 Aug; 34(8):818-25. PubMed ID: 24854996 [TBL] [Abstract][Full Text] [Related]
12. Low-Dose Systemic Alteplase (tPA) for the Treatment of Pulmonary Embolism. Brandt K; McGinn K; Quedado J Ann Pharmacother; 2015 Jul; 49(7):818-24. PubMed ID: 25857308 [TBL] [Abstract][Full Text] [Related]
13. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Levine M; Hirsh J; Weitz J; Cruickshank M; Neemeh J; Turpie AG; Gent M Chest; 1990 Dec; 98(6):1473-9. PubMed ID: 2123152 [TBL] [Abstract][Full Text] [Related]
17. The role of noninvasive tests versus pulmonary angiography in the diagnosis of pulmonary embolism. Cheely R; McCartney WH; Perry JR; Delany DJ; Bustad L; Wynia VH; Griggs TR Am J Med; 1981 Jan; 70(1):17-22. PubMed ID: 7457486 [TBL] [Abstract][Full Text] [Related]
19. Catheter-directed, ultrasound-assisted thrombolysis is a safe and effective treatment for pulmonary embolism, even in high-risk patients. Lee KA; Cha A; Kumar MH; Rezayat C; Sales CM J Vasc Surg Venous Lymphat Disord; 2017 Mar; 5(2):165-170. PubMed ID: 28214482 [TBL] [Abstract][Full Text] [Related]